Nicholas Schwab

Nicholas Schwab

Auto-generated profile, based on publicly available information

Nicholas Schwab

Department of Neurology, University of Muenster, Muenster, Germany

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2010 in Blood
Verified
Journal Article
Closed access
PDF file
Christoph KleinschnitzChristoph Kleinschnitz
Christoph Kleinschnitz
NSNicholas Schwab
Nicholas Schwab
PKPeter Kraft
Peter Kraft
IHIna Hagedorn
Ina Hagedorn
ADAngela Dreykluft
Angela Dreykluft
GSGuido Stoll
Guido Stoll
T cells contribute to the pathophysiology of ischemic stroke by yet unknown mechanisms. Mice with transgenic T-cell receptors (TCRs) and mutations in costimulatory molecules were used to define the minimal immunologic requirements for T cell–mediated ischemic brain damage. Stroke was induced in recombination activating gene 1–deficient (RAG1−/−) mice devoid of T and B cells, RAG1−/− mice reconstituted with B cells or T cells, TCR-transgenic mice bearing 1 single CD8+ (2C/RAG2, OTI/RAG1 mice) or CD4+ (OTII/RAG1, 2D2/RAG1 mice) TCR, mice lacking accessory molecules of TCR stimulation (CD28−/−, PD1−/−, B7-H1−/− mice), or mice deficient in nonclassical T cells (natural killer T [NKT] and γδ T cells) by transient middle cerebral artery occlusion (tMCAO). Stroke outcome was assessed at day 1. RAG1−/− mice and RAG1−/− mice reconstituted with B cells developed significantly smaller brain infarctions compared with controls, but thrombus formation after FeCl3-induced vessel injury was unimpaired. In contrast, TCR-transgenic mice and mice lacking costimulatory TCR signals were fully susceptible to tMCAO similar to mice lacking NKT and γδ T cells. These findings were corroborated by adoptive transfer experiments. Our data demonstrate that T cells critically contribute to cerebral ischemia, but their detrimental effect neither depends on antigen recognition nor TCR costimulation or thrombus formation.

9 May 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CGCatharina C. Gross
Catharina C. Gross
ASAndreas Schulte-Mecklenbeck
Andreas Schulte-Mecklenbeck
ARAnna Rünzi
Anna Rünzi
TKTanja Kuhlmann
Tanja Kuhlmann
APAnita Posevitz-Fejfár
Anita Posevitz-Fejfár
HWHeinz Wiendl
Heinz Wiendl
Significance: The importance of natural killer (NK) cells in the control of autoimmunity has recently attracted considerable attention. The current study revealed NK cells as additional players in controlling T-cell activity in CNS autoimmunity. NK-mediated control of T-cell activity in multiple sclerosis (MS) is dysregulated and caused by impaired DNAX accessory molecule-1/CD155 interaction between NK cells and CD4+T cells. Therapeutic immune modulation of the IL-2 receptor with daclizumab, which has just successfully passed a phase III study in relapsing-remitting MS, not only enhances the cytolytic activity of NK cells but also restores defective NK-mediated immune regulation by increasing the proportion of CD155-expressing CD4+T cells, thus rendering CD4+T cells most likely more sensitive to NK-mediated lysis.

18 August 2014 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TSTilman Schneider-Hohendorf
Tilman Schneider-Hohendorf
JRJan Rossaint
Jan Rossaint
HMHema Mohan
Hema Mohan
DBDaniel Böning
Daniel Böning
JBJohanna Breuer
Johanna Breuer
HWHeinz Wiendl
Heinz Wiendl
The focus of this study is the characterization of human T cell blood–brain barrier migration and corresponding molecular trafficking signatures. We examined peripheral blood and cerebrospinal fluid immune cells from patients under long-term anti–very late antigen-4 (VLA-4)/natalizumab therapy (LTNT) and from CNS specimens. LTNT patients’ cerebrospinal fluid T cells exhibited healthy central-/effector-memory ratios, but lacked CD49d and showed enhanced myeloma cell adhesion molecule (MCAM) expression. LTNT led to an increase of PSGL-1 expression on peripheral T cells. Although vascular cell adhesion molecule-1 (VLA-4 receptor) was expressed at all CNS barriers, P-selectin (PSGL-1-receptor) was mainly detected at the choroid plexus. Accordingly, in vitro experiments under physiological flow conditions using primary human endothelial cells and LTNT patients’ T cells showed increased PSGL-1–mediated rolling and residual adhesion, even under VLA-4 blockade. Adhesion of MCAM+/TH17 cells was not affected by VLA-4 blocking alone, but was abrogated when both VLA-4 and MCAM were inhibited. Consistent with these data, MCAM+ cells were detected in white matter lesions, and in gray matter of multiple sclerosis patients. Our data indicate that lymphocyte trafficking into the CNS under VLA-4 blockade can occur by using the alternative adhesion molecules, PSGL-1 and MCAM, the latter representing an exclusive pathway for TH17 cells to migrate over the blood–brain barrier.

29 January 2009 in Brain
Verified
Journal Article
Open access
PDF file
NSNicholas Schwab
Nicholas Schwab
CBChristian G. Bien
Christian G. Bien
AWAnne Waschbisch
Anne Waschbisch
ABAlbert Becker
Albert Becker
GVGiles H. Vince
Giles H. Vince
HWHeinz Wiendl
Heinz Wiendl
Rasmussen encephalitis (RE) is a rare neurological disorder of childhood characterized by uni-hemispheric inflammation, progressive neurological deficits and intractable focal epilepsy. Destruction of neurons and astrocytes by cytotoxic CD8 T cells has been proposed as a pathogenic mechanism underlying this enigmatic disorder. We tested this hypothesis by analysing the clonal composition and T-cell receptor (TCR) repertoire of CD4+ and CD8+ T cells using complementarity determining region 3 (CDR3) spectratyping from peripheral blood and corresponding CNS specimens. Severe perturbations of the TCR repertoire were found in brain infiltrates from all specimens (n = 5). Clonal expansions, as evidenced by peripheral blood analysis (n = 14), belonged to the CD8+ T-cell subset, while CD4+ cells showed normal distributions. Some of those expansions were analysed in the respective CNS specimens by histochemistry. The stainings showed Vβ specific T cells containing the cytotoxic molecule granzyme B and lying in close appositions to NeuN+ neurons and GFAP+ astrocytes. Analysis of corresponding CNS/blood specimens revealed overlapping but also CNS-restricted expansions of certain TCR clonotypes suggesting expansions of T cells within the target organ itself. Longitudinal analysis of peripheral blood samples (n = 5) demonstrated dominance but also longitudinal persistence of specific CD8 T-cell clones over time. The Vβ/Jβ usage, length of the CDR3, and biochemical characteristics of the CDR3 amino acids suggested high similarities putatively related to common driving antigen(s) without shared clones. Taken together, our data strongly support the hypothesis of an antigen-driven MHC class-I restricted, CD8+ T cell-mediated attack against neurons and astrocytes in the CNS dominating the pathogenesis in RE.

1 May 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LKLuisa Klotz
Luisa Klotz
MEMelanie Eschborn
Melanie Eschborn
MLMaren Lindner
Maren Lindner
MLMarie Liebmann
Marie Liebmann
MHMartin Herold
Martin Herold
HWHeinz Wiendl
Heinz Wiendl
Inhibition of a mitochondrial enzyme during multiple sclerosis treatment modulates antigen-specific T cell responses in an affinity-dependent fashion.

3 September 2013 in Neurology
Verified
Journal Article
Closed access
PDF file
NSNicholas Schwab
Nicholas Schwab
TSTilman Schneider-Hohendorf
Tilman Schneider-Hohendorf
VPVilmos Posevitz
Vilmos Posevitz
JBJohanna Breuer
Johanna Breuer
KGKerstin Göbel
Kerstin Göbel
HWHeinz Wiendl
Heinz Wiendl
Objective: To find biomarkers identifying patients at risk for the development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment. Methods: Patients were recruited from 10 European and US cohorts. Of 289 patients with multiple sclerosis (MS), 224 had been treated with natalizumab (18–80 months), 21 received other immune-modulatory treatments, and 28 were untreated. We had access to samples from 16 natalizumab PML patients. Eight of these patients had given blood before the diagnosis of PML. We also analyzed non-natalizumab-treated patients who developed PML (n = 10) and age- and sex-matched healthy donors (n = 31). All flow cytometric assessments were done on previously cryopreserved, viable peripheral blood mononuclear cells. Results: The percentage of l-selectin-expressing CD4+ T cells was significantly lower in patients treated long-term with natalizumab (40.2%) when compared with patients not receiving natalizumab treatment (47.2%; p = 0.016) or healthy controls (61.0%; p < 0.0001). An unusually low percentage (9-fold lower; 4.6%) was highly correlated with the risk of developing PML in the patient group with available pre-PML samples when compared with non-PML natalizumab-treated patients (p ≤ 0.0001). Samples were gathered between 4 and 26 months before PML diagnosis. Conclusions: The cell-based assessment of the percentage of l-selectin-expressing CD4 T cells could provide an urgently needed biomarker for individual PML risk assessment.